# DESCRIPTION

## FIELD OF THE INVENTION

- relate to chimeric antigen receptors

## BACKGROUND OF THE INVENTION

- motivate T cell manipulation
- introduce chimeric antigen receptors
- discuss limitations of current CAR constructs

## SUMMARY OF THE INVENTION

- identify need for pure Treg populations
- introduce method for optimal CAR-mediated activation
- describe advantage of CD137 co-stimulatory domain
- outline benefits for therapeutic use

## DETAILED DESCRIPTION OF THE INVENTION

- define CAR structure
- describe antigen binding domain
- describe transmembrane domain
- describe cytoplasmic signaling domain
- describe target cell and antigen
- describe alternative antigen binding domain
- describe soluble antigen
- describe composition of Treg cells and CAR
- describe pharmaceutical composition
- describe combination of pharmaceutical compositions
- describe method for enrichment of activated Treg cells
- describe genetic modification of Treg cells
- describe activation and isolation of Treg cells
- describe use of CAR for analyzing Treg activation efficiency
- define CAR domains
- describe CAR modification
- explain Treg activation
- summarize Treg activation markers
- describe method for comparing CARs
- outline method steps
- describe genetic modification of Treg cells
- list methods for genetic modification
- describe method for testing antigen formulations
- outline method steps for testing antigen formulations
- describe DNA or RNA construct transfection
- explain cell isolation and enrichment
- describe cell expansion and activation
- outline automated process for generating genetically modified Tregs
- describe use of closed system for cell modification
- explain therapeutic use of engineered Tregs
- describe formulation of Treg cells for administration
- outline modes of administration
- describe dosage and administration of soluble antigens

### Definitions

- define CAR structure
- describe extracellular domain
- explain transmembrane domain
- detail cytoplasmic signaling domain
- define antigen binding domain
- describe spacer/hinge region
- explain effector function
- detail primary cytoplasmic signaling domains
- describe secondary cytoplasmic signaling domains
- explain ITAM-containing primary cytoplasmic signaling domains
- detail co-stimulatory signaling regions
- describe CD137 CAR and CD28 CAR
- explain suicide switch
- define antibody and antibody fragments
- describe antigen
- explain soluble antigen
- detail dextran as a soluble antigen
- define target cell
- define autoimmunity
- define transplant rejection
- define allergy
- define chronic inflammatory diseases
- define CARs and related terms
- define isolated and purified
- define subject and related terms
- define therapeutically effective amount
- define specifically binds
- define engineered cell and genetically modified cell
- define various other terms

### EMBODIMENTS

- generate Treg expressing CAR with CD3zeta and CD137 signaling domains
- isolate Tregs expressing CAR after antigen-specific activation
- obtain Tregs from various sources and enrich using centrifugation or sorting
- engineer Tregs to express CD137-CD3ζ-CAR and isolate using fluorescent or magnetic sorting
- expand engineered Tregs in presence of exogenous antigen or polyclonal stimulation
- use CD137-CD3ζ-CAR for treatment of inflammatory disease or autoimmune disease

## Methods

### CAR Constructs

- generate CAR constructs

### Treg Isolation and Transduction

- isolate Treg cells
- transduce Treg cells with CAR constructs

### Flow Cytometry

- analyze cell surface expression

### Quantification of Gene Expression

- quantify gene expression by qRT-PCR

